RDEA3170 Monotherapy in Subjects With Gout

PHASE2CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

July 31, 2014

Conditions
Gout
Interventions
DRUG

Placebo

DRUG

RDEA3170 5 mg

DRUG

RDEA3170 10 mg

DRUG

RDEA3170 12.5 mg

Trial Locations (49)

10016

New York

16602

Altoona

23114

Midlothian

23219

Richmond

23462

Virginia Beach

27103

Winston-Salem

28150

Shelby

28152

Shelby

28210

Charlotte

28401

Wilmington

28602

Hickory

29303

Spartanburg

29464

Mt. Pleasant

29615

Greenville

29651

Greer

29732

Rock Hill

30338

Dunwoody

32205

Jacksonville

33027

Pembroke Pines

33606

Tampa

33880

Winter Haven

35235

Birmingham

36542

Gulf Shores

36608

Mobile

37174

Spring Hill

39202

Jackson

40503

Lexington

42701

Elizabethtown

43551

Perrysburg

44904

Willoughby Hills

45224

Cincinnati

58103

Fargo

60031

Gurnee

70006

Metairie

77098

Houston

80220

Denver

80918

Colorado Springs

83646

Meridian

84010

Bountiful

85308

Glendale

85381

Peoria

85704

Tucson

89502

Reno

92618

Irvine

92805

Anaheim

94578

San Leandro

94582

San Ramon

95670

Gold River

96814

Honolulu

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY

NCT01927198 - RDEA3170 Monotherapy in Subjects With Gout | Biotech Hunter | Biotech Hunter